February 19, 2018 (YouTube) Constantine Tam, MD, FRACP, FRCPA, of Peter MacCallum Cancer Centre, Melbourne, Australia.
Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Dr. Tam discusses the current limitation of the collection of high quality originator T-cells from patients in the treatment of chronic lymphocytic leukemia (CLL). He refers to the results of a study investigating whether ibrutinib pre-treatment could improve the production process and outcomes.
Dr. Tam also gives his predictions on the future of CAR T-cell therapy for CLL, including whether it could replace autologous stem cell transplantation (ASCT).
